Hexima Investor Updates

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

read more

Archives